WallStSmart

Femasys Inc (FEMY)vsMedline Inc. Class A Common Stock (MDLN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medline Inc. Class A Common Stock generates 1270558% more annual revenue ($29.14B vs $2.29M). MDLN leads profitability with a 3.3% profit margin vs 0.0%. MDLN earns a higher WallStSmart Score of 55/100 (C-).

FEMY

Hold

38

out of 100

Grade: F

Growth: 8.0Profit: 2.5Value: 5.0Quality: 5.5
Piotroski: 3/9Altman Z: -11.43

MDLN

Buy

55

out of 100

Grade: C-

Growth: 7.3Profit: 5.5Value: 4.7Quality: 6.5
Piotroski: 4/9Altman Z: 1.79

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

FEMY1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
39.9%10/10

Revenue surging 39.9% year-over-year

MDLN2 strengths · Avg: 9.0/10
EPS GrowthGrowth
1258.0%10/10

Earnings expanding 1258.0% YoY

Price/BookValuation
2.5x8/10

Reasonable price relative to book value

Areas to Watch

FEMY4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$925,1803/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

MDLN4 concerns · Avg: 3.5/10
P/E RatioValuation
31.4x4/10

Premium valuation, high expectations priced in

Altman Z-ScoreHealth
1.794/10

Distress zone — elevated risk

Profit MarginProfitability
3.3%3/10

3.3% margin — thin

Debt/EquityHealth
1.123/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : FEMY

The strongest argument for FEMY centers on Revenue Growth. Revenue growth of 39.9% demonstrates continued momentum.

Bull Case : MDLN

The strongest argument for MDLN centers on EPS Growth, Price/Book. Revenue growth of 10.7% demonstrates continued momentum.

Bear Case : FEMY

The primary concerns for FEMY are EPS Growth, Market Cap, Profit Margin.

Bear Case : MDLN

The primary concerns for MDLN are P/E Ratio, Altman Z-Score, Profit Margin. Thin 3.3% margins leave little buffer for downturns.

Key Dynamics to Monitor

FEMY profiles as a hypergrowth stock while MDLN is a value play — different risk/reward profiles.

FEMY is growing revenue faster at 39.9% — sustainability is the question.

MDLN generates stronger free cash flow (316M), providing more financial flexibility.

Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MDLN scores higher overall (55/100 vs 38/100) and 10.7% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Femasys Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Femasys Inc. is an innovative medical technology company dedicated to transforming women's healthcare through its proprietary solutions for diagnosing and treating gynecological conditions. With a focus on non-surgical alternatives, Femasys is addressing prevalent issues such as uterine fibroids and contraception, positioning itself as a key player in the growing field of women’s health. As demand for minimally invasive treatments continues to rise, the company is strategically equipped to enhance patient outcomes and efficiency in healthcare delivery. By concentrating on significant unmet needs, Femasys aims to set new standards for care in this essential sector.

Medline Inc. Class A Common Stock

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. The company is headquartered in Northfield, Illinois.

Visit Website →

Want to dig deeper into these stocks?